Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma

1Sanofi Specialty Care, Cambridge, MA;

2Massachusetts College of Pharmacy and Health Sciences University, Manchester, NH;

3Faculty of Medicine, Department of Medical and Surgical Specialties, Transilvania University of Brasov, Romania; and

4Faculty of Medicine, Department of Fundamental Disciplines and Clinical Prevention, Transilvania University of Brasov, Brasov, Romania.

*Address for correspondence: Lorena Dima, MD, PhD, Professor of Pharmacology, Transilvania University of Brasov, Faculty of Medicine, Department of Fundamental Disciplines and Clinical Prevention, 56 Nicolae Bălcescu Str., 500019, Brasov, Romania. E-mail: [email protected]

The authors have no conflicts of interest to declare.

This article is part of a series evaluating drugs recently approved by the U.S. Food and Drug Administration. The series is coordinated by Timothy Nguyen, PharmD and Kristine Willett, PharmD.

留言 (0)

沒有登入
gif